Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-12-25
2007-12-25
Woitach, Joseph (Department: 1633)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A, C424S093100, C536S023100
Reexamination Certificate
active
10139763
ABSTRACT:
The invention is directed to novel combinations of liver specific enhancers and promoter elements for achieving persistent transgene expression in the liver. The liver specific enhancer elements may be derived from either the human serum albumin, prothrombin, α-1microglobulin or aldolase genes in single copies or in multimerized form linked to elements derived from the cytomegalovirus intermediate early (CMV), α-1-antitrypsin or albumin promoters. In a preferred embodiment of the invention, an adenoviral vector comprising a liver specific enhancer/promoter combination operably linked to a transgene is administered to recipient cells. In other embodiments of the invention, adeno-associated viral vectors, retroviral vectors, lentiviral vectors or a plasmid comprising the liver specific enhancer/promoter combination linked to a transgene is administered to recipient cells. Also within the scope of the invention are promoter elements derived from the human prothrombin gene and the β-fibrinogen gene.
REFERENCES:
patent: 5965541 (1999-10-01), Wickham et al.
patent: 2002/0155095 (2002-10-01), Nagabhushan et al.
patent: 2003/0224508 (2003-12-01), Ill et al.
patent: 4339922 (1994-10-01), None
patent: 4407859 (1995-03-01), None
patent: 0589851 (1994-03-01), None
patent: WO 95/11308 (1995-04-01), None
patent: WO 97/04117 (1997-02-01), None
patent: WO 98/09524 (1998-03-01), None
patent: WO 99/29848 (1999-06-01), None
patent: 99/36557 (1999-07-01), None
patent: WO 99/36557 (1999-07-01), None
Rouet. Nucleic Acids Research 1995, vol. 23, No. 3, p. 395-404.
Okuyama et al. (Human Gene Therapy, 7: 637-645, Mar. 1996.
Kay et al. Human Gene Therapy 3:641-647, 1992.
Greenberg et al. Proc. Natl. Acad. Sci. USA 92:12347-12351.
Sabourin et al. The Journal of Biological Chemistry 271:3469-3473, 1996.
Darzan et al (Journal of Surgical Research 59:299-304, 1995.
Allan, Charles M. et al., Two Hepatic Enhancers, HCR.1 and HCR.2, Coordinate the Liver Expression of the Entire Human Apolipoprotein E/C-I/C-IV/C-II Gene Cluster, The Journal of Biological Chemistry, vol. 272, No. 46, Nov. 14, 1997, pp. 29113-29119; by the American Society for Biochemistry and Molecular Biology, Inc.
Armentano, Donna et al., Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors, Journal of Virology, vol. 71, No. 3, Mar. 1997, pp. 2408-2416; American Society for Microbiology.
Armentano, Donna et al., E4ORF3 Requirement for Achieving Long-Term Transgene Expression from the Cytomegalovirus Promoter in Adenovirus Vectors, Journal of Virology, Aug. 1999, vol. 73, No. 8, pp. 7031-7034; American Society for Microbiology.
Bell, Adam C. et al., The Protein CTCF Is Required for the Enhancer Blocking Activity of Vertebrate Insulators, Cell, vol. 98, Aug. 6, 1999, pp. 387-396; Cell Press.
Berkner, K.L., Expression of Heterologous Sequences in Adenoviral Vectors, Current Topics in Microbiology and Immunology, vol. 158, pp. 39-66; Springer-Verlag Berlin Heidleberg 1992.
Brough, Douglas E. et al., Activation of Transgene Expression by Early Region 4 is Responsible for a High Level of Persistent Transgene Expression from Adenovirus Vectors In Vivo, Journal of Virology, Dec. 1997, vol. 71, No. 12, pp. 9206-9213; American Society for Microbiology.
Chow, Billy, K.C. et al., Characterization of a Novel Liver-Specific Enhancer in the Human Prothrombin Gene, The Journal of Biological Chemistry, vol. 266, No. 28, Oct. 5, 1991, pp. 18927-18933; The American Society for Biochemistry and Molecular Biiology, Inc.
Ciliberto, Gennaro et al., Cell-Specific Expression of a Transfected Human alpha 1-Antitrypsin Gene, Cell, vol. 41, Jun. 1985, pp. 531-540; MIT.
Connelly, Sheila et al., Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy, Blood, vol. 91, No. 9, May 1, 1998, pp. 3273-3281; The American Society of Hematology.
Crystal, Ronald G. et al., Administration of an Adenovirus Containing the Human CFTR cDNA to the Respiratory Tract of Individuals with Cystic Fibrosis, Nature Genetics, vol. 8, Sep. 1994, pp. 42-61.
Dedieu, Jean-Francois et al., Long-Term Gene Delivery into the Livers of Immunocompetent Mice with E1/E4-Defective Adenoviruses, Journal of Virology, Jun. 1997, vol. 71, No. 6, pp. 4626-4637; American Society for Microbiology.
Donello, John E. et al., Woodchuck Hepatitis Virus Contains a Tripartite Posttranscriptional Regulatory Element, Journal of Virology, Jun. 1998, vol. 72, No. 6, pp. 5085-5092; American Society for Microbiology.
Frain, Monique et al., Binding of a Liver-Specific Factor to the Human Albumin Gene Promoter and Enhancer, Molecular and Cellular Biology, Mar. 1990, vol. 10, No. 3, pp. 991-999; American Society for Microbiology.
Gregori, Claudine et al., Characterization of the Aldolase B Intronic Enhancer, The Journal of Biological Chemistry, vol. 273, No. 39, 1998, pp. 25237-25243; The American Society for Biochemistry and Molecular Biology, Inc.
Guo, ZS et al., Evaluation of Promoter Strength for Hepatic Gene Expression In Vivo Following Adenovirus-Mediated Gene Transfer, Gene Therapy (1996), vol. 3, pp. 802-810; Stockton Press.
Hafenrichter, Daniel G. et al., Liver-Directed Gene Therapy: Evaluation of Liver Specific Promoter Elements, Journal of Surgical Research, vol. 56, pp. 510-517 (1994); Academic Press, Inc.
Hafenrichter, Daniel G. et al., Quantitative Evaluation of Liver-Specific Promoters from Retroviral Vectors after in Vivo Transduction of Hepatocytes, Blood, vol. 84, No. 10, Nov. 15, 1994, pp. 3394-3404; The American Society of Hematology.
Hayashi, Yoshitake et al., Identification and Characterization of Two Enhancers of the Human Albumin Gene, The Journal of Biological Chemistry, vol. 267, No. 21, Jul. 25, 1992, pp. 14580-14585; The American Society for Biochemistry and Molecular Biology.
Holcik, Martin et al., Four Highly Stable Eukaryotic mRNAs-Assemble 3′ Untranslated Region RNA-Protein Complexes Sharing Cis and Trans Components, Proc. Natl. Acad. Sci., USA, vol. 94, pp. 2410-2414, Mar. 1997; Developmental Biology.
Huber, P. et al., Human Beta-Fibrinogen Gene Expression, The Journal of Biological Chemistry, vol. 265, No. 10, Apr. 5, 1990, pp. 5695-5701; The American Society for Biochemistry and Molecular Biology, Inc.
Ill, Charles R. et al., Optimization of the Human Factor VIII Complementary DNA Expression Plasmid for Gene Therapy of Hemophilia A, Blood Coagulation and Fibrinolysis, vol. 8, Suppl. 2, (1997), pp. S23-S30; Rapid Science Publishers.
Jolly, Douglas, Cancer Gene Therapy, vol. 1, No. 1, 1994, pp. 51-64; Nature Publishing Group.
Morral, Nurla et al., High Doses of a Helper-Dependent Adanoviral Vector Yield Supraphysiological Levels of Alpha 1-Antitrypsin with Negligible Toxicity, Human Gene Therapy, vol. 9, Dec. 10, 1998, pp. 2709-2716; Mary Ann Liebert, Inc.
Nakai, Hiroyuki et al., Adeno-Associated Viral Vector-Mediated Gene Transfer of Human Blood Coagulation Factor IX into Mouse Liver, Blood, vol. 91, No. 12, Jun. 15, 1998, pp. 4600-4607; The American Society of Hematology.
Okuyama, Torayuki et al., Liver-Directed Gene Therapy: A Retroviral Vector with a Complete LTR and the ApoE Enhancer-alpha 1-Antitrypsin Promoter Dramatically Increases Expression of Human alpha 1-Antitrypsin In Vivo, Human Gene Therapy, vol. 7, Mar. 20, 1996, pp. 637-645; Mary Ann Liebert, Inc.
Ponder, Katherine Parker et al., Evaluation of Relative Promoter Strength in Primary Hepatocytes Using Optimized Lipofection, Human Gene Therapy, vol. 2, (1991), pp. 41-52; Mary Ann Liebert, Inc., Publishers.
Rettinger, Steven D. et al., Liver-Directed Gene Therapy: Quantitative Evaluation of Promoter Elements by Using In Vivo Retroviral Transduction, Proc. Natl. Acad. Sci. USA, vol. 91, Feb. 1994, pp. 1460-1464; Genetics.
Rich, Devra P. et al., Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis, Human Gene Therapy,vol. 4, (1993), pp. 461-476; Mary Ann Liebert, Inc., Publishers.
Rouet, Philippe et al., A Potent Enhancer Made of Clustered Liver-Specific Elements in the Transcription Control Sequences of Human Alpha
Armentano Donna
Souza David W.
Wadsworth Samuel C.
Genzyme Corporation
Kelly Robert M.
Woitach Joseph
LandOfFree
Regulatory elements for delivery to the liver does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulatory elements for delivery to the liver, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulatory elements for delivery to the liver will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887479